BERKELEY, Calif., and VANCOUVER, British Columbia, June 9, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held on June 25 – 26, 2020.
Details of BriaCell’s oral presentation are the following:
Event: 3rd Annual Next-Gen Immuno-Oncology Congress
Date: June 26, 2020
Time: 9:30 Eastern Time
Title: Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf Approach
Session: Stream B, Immune Checkpoint Inhibitors, Immune Modulating Agents & Tumor Micro-Environment
Following the presentations, copies of the presentations will be posted on https://briacell.com/novel-technology/scientific-publications/.
About Next-Gen Immuno-Oncology Congress
The 3rd Annual Next-Gen Immuno-Oncology Congress provides an opportunity for experts in the field to discuss the latest in antibodies, cellular therapy and immune-checkpoint research, learn of the new case studies of immuno-oncology projects in development, and contribute to interactive Q&A sessions with their peers to deliberate key topics of relevance, explore the latest platforms and technologies on the market for development, and discuss the best tools for their research in immuno-oncology.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation (also known as “forward-looking statements”) which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.
These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell’s current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
William V. Williams, MD
President & CEO
Phone: 1-888-485-6340
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: [email protected]
Phone: 1-888-485-6340